| P50 | author | Anne Le | Q40504142 |
| | Tu Nguyen | Q88342943 |
| P2093 | author name string | Tu Nguyen | |
| | Anne Le | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| | Metabolism of kidney cancer: from the lab to clinical practice | Q24600512 |
| | mTOR signaling in growth control and disease | Q24634174 |
| | Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 |
| | Integrated molecular analysis of clear-cell renal cell carcinoma | Q27852382 |
| | von Hippel-Lindau tumor suppressor: not only HIF's executioner | Q28263422 |
| | Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids | Q28265196 |
| | Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells | Q28274690 |
| | Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis | Q29615683 |
| | Hepatocellular carcinoma | Q29616359 |
| | Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction | Q29616653 |
| | Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. | Q30353189 |
| | Metabolic profiling reveals key metabolic features of renal cell carcinoma | Q33511655 |
| | UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer | Q33682182 |
| | Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications | Q35137857 |
| | The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels | Q35215557 |
| | Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. | Q35621265 |
| | The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. | Q35764439 |
| | Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation. | Q36545983 |
| | Phosphatidylcholine and the CDP-choline cycle. | Q36581975 |
| | HIF-1 mediates the Warburg effect in clear cell renal carcinoma | Q36841614 |
| | HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation | Q36907933 |
| | Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality | Q36930538 |
| | LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer. | Q37015893 |
| | Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma | Q37054261 |
| | Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors | Q37069569 |
| | LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer | Q37165231 |
| | MYC-induced cancer cell energy metabolism and therapeutic opportunities | Q37438881 |
| | Resistance to targeted therapy in renal-cell carcinoma | Q37606744 |
| | The altered metabolism of tumors: HIF-1 and its role in the Warburg effect | Q37629203 |
| | Rethinking the Warburg effect with Myc micromanaging glutamine metabolism | Q37677940 |
| | Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133. | Q37734673 |
| | The ins and outs of phosphatidylethanolamine synthesis in Trypanosoma brucei | Q38046394 |
| | Targeting metabolic changes in cancer: novel therapeutic approaches | Q38178298 |
| | Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. | Q38534459 |
| | Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma | Q38722204 |
| | Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis | Q38738125 |
| | Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification | Q38770158 |
| | Genetic profiling of hepatocellular carcinoma using next-generation sequencing. | Q38855069 |
| | In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation | Q39030433 |
| | Cancer Statistics, 2017. | Q39038674 |
| | Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft | Q39523939 |
| | SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis. | Q40056771 |
| | Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma | Q40987028 |
| | The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. | Q41923187 |
| | Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. | Q46204388 |
| | Single cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. | Q48282479 |
| | Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy. | Q49923401 |
| | Renal cell carcinoma | Q56019530 |
| | Hepatocellular carcinoma | Q57756376 |
| | Cellular origin of renal cell carcinoma--an immunohistological study on monoclonal antibodies | Q67845142 |
| | Antioxidant reactions of vitamin E in the perfused rat liver: product distribution and effect of dietary vitamin E supplementation | Q73123220 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cancer | Q623031 |
| P304 | page(s) | 107-118 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Advances in Experimental Medicine and Biology | Q4686385 |
| P1476 | title | The Metabolism of Renal Cell Carcinomas and Liver Cancer | |
| P478 | volume | 1063 | |